Viyash Scientific Ltd Downgraded to Sell Amid Technical and Fundamental Concerns

Quality Assessment: Weak Long-Term Fundamentals Temper Recent Gains

While Viyash Scientific has demonstrated outstanding financial performance in the third quarter of FY25-26, underlying quality metrics remain a concern. The company’s average Return on Capital Employed (ROCE) over the long term stands at a modest 7.40%, signalling limited efficiency in generating returns from its capital base. This figure contrasts sharply with the sector’s higher benchmarks and raises questions about sustainable profitability.

Moreover, the company’s net sales have grown at an annualised rate of 14.17% over the past five years, with operating profit increasing at 12.25% annually. Although these growth rates are positive, they are relatively subdued compared to industry leaders, indicating moderate expansion rather than robust acceleration. The company’s ability to service debt is also under scrutiny, with a Debt to EBITDA ratio of 1.32 times, suggesting a higher leverage risk compared to peers.

Valuation: Expensive Despite Discount to Peers

Viyash Scientific’s valuation presents a nuanced picture. The company’s ROCE for the half-year period has improved to 18.1%, yet it carries an expensive valuation with an Enterprise Value to Capital Employed ratio of 7.5. This elevated multiple implies that investors are pricing in significant growth expectations. However, the stock currently trades at a discount relative to its peers’ historical valuations, which may offer some cushion for value-oriented investors.

Over the past year, the stock has delivered a strong return of 28.11%, outperforming the Sensex which declined by 4.68% during the same period. Profit growth has been particularly impressive, with net profits rising by 138.8%, resulting in a PEG ratio of 1.6. This suggests that while the stock is expensive on traditional metrics, its earnings growth partially justifies the premium.

Financial Trend: Mixed Signals Amid Strong Quarterly Results

Viyash Scientific has reported outstanding quarterly results for Q3 FY25-26, with operating profit growth surging by 78.2%. The company has maintained a positive earnings trajectory for eight consecutive quarters, underscoring operational resilience. The half-year ROCE peaked at 18.65%, and the operating profit to interest coverage ratio reached a robust 10.49 times, reflecting strong earnings relative to interest obligations. Additionally, the debt-to-equity ratio remains low at 0.61 times, indicating prudent capital structure management.

Despite these encouraging short-term financial metrics, the company’s long-term growth outlook remains subdued. Its net sales and operating profit growth rates over five years, while positive, do not match the pace of sector leaders. This disparity contributes to the cautious stance reflected in the downgrade.

Technical Analysis: Shift from Mildly Bullish to Sideways Trend

The most significant factor driving the downgrade is the deterioration in technical indicators. The technical trend has shifted from mildly bullish to sideways, signalling uncertainty in price momentum. Key technical metrics reveal a predominantly bearish outlook on weekly and monthly timeframes. The Moving Average Convergence Divergence (MACD) is mildly bearish on both weekly and monthly charts, while the Know Sure Thing (KST) indicator also shows bearish signals.

The Relative Strength Index (RSI) remains neutral with no clear signal, and Bollinger Bands present a mixed picture—bearish on the weekly scale but mildly bullish monthly. Moving averages on the daily chart are mildly bullish, yet this is insufficient to offset the broader negative technical sentiment. Dow Theory assessments indicate a mildly bearish weekly trend and no definitive monthly trend. On-balance volume (OBV) shows no clear trend, further emphasising the sideways momentum.

These technical signals collectively suggest limited upside potential in the near term, justifying a more cautious investment stance.

Stock Performance Relative to Benchmarks

Examining Viyash Scientific’s returns relative to the Sensex provides additional context. The stock has underperformed the benchmark over the past week, declining by 4.43% compared to the Sensex’s modest 0.17% gain. Over one month, the stock returned 4.64%, slightly lagging the Sensex’s 5.04%. Year-to-date, the stock is down 3.56%, though this is better than the Sensex’s 9.63% decline.

Longer-term performance is more favourable, with the stock delivering 28.11% returns over one year and an impressive 149.29% over three years, significantly outperforming the Sensex’s 26.15% gain in the same period. However, over five years, the stock has declined by 31.30%, contrasting with the Sensex’s 58.22% rise, and over ten years, it has returned 30.02% versus the Sensex’s 204.87%. This mixed performance underscores the stock’s volatility and cyclical nature.

Ownership and Market Capitalisation

Viyash Scientific remains a small-cap stock with a market capitalisation grade reflecting its size. The majority shareholding is held by promoters, which often provides stability but can also limit liquidity. The stock’s current price stands at ₹200.75, down 1.91% from the previous close of ₹204.65. The 52-week trading range spans from ₹144.85 to ₹260.30, indicating significant price volatility over the past year.

Conclusion: Downgrade Reflects Caution Amid Mixed Signals

The downgrade of Viyash Scientific Ltd from Hold to Sell by MarketsMOJO on 5 May 2026 is driven primarily by a shift in technical indicators from mildly bullish to sideways and bearish signals on key momentum metrics. Despite strong recent quarterly earnings and solid profit growth, the company’s long-term fundamental quality remains weak, with modest ROCE and moderate sales growth. Valuation metrics suggest the stock is expensive relative to capital employed, though it trades at a discount to peers historically.

Investors should weigh the company’s impressive short-term financial performance against its subdued long-term growth prospects and deteriorating technical outlook. The stock’s mixed returns relative to the Sensex and sector peers further underscore the need for caution. For those considering exposure to Viyash Scientific, a thorough comparison with alternative opportunities in Pharmaceuticals & Biotechnology is advisable.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →